Lab
Pathology Reference Laboratory, L.L.C.
Pathology Reference Laboratory, L.L.C. was paid $4.70M by Medicaid between Jan 2018 and Dec 2024, across 34 billing codes. Its largest line is 87491, Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe — 16% of everything it billed.
33Billing provider infoPATHOLOGY REFERENCE LABORATORY, L.L.C.
SAN ANTONIO, TX 78229
SAN ANTONIO, TX 78229
33aNPI1538157086assigned 10/10/2005
33bProvider typeClinical Medical Laboratory
28Total paid$4.70M
24GClaims182,213
24DCodes billed34
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other Clinical Medical Laboratory providers in Texas
Rank by total paid#28 of 436
Median peer was paid$17K
This provider vs. median272×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 8,984 | $225K | |
| 2019 | 7,843 | $184K | |
| 2020 | 23,679 | $533K | |
| 2021 | 50,075 | $1.24M | |
| 2022 | 41,615 | $1.08M | |
| 2023 | 29,806 | $813K | |
| 2024incomplete | 20,211 | $618K |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | 16% | 30,821 | 29,985 | $761K |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | 16% | 30,560 | 29,747 | $752K |
| 81513 | 11% | 8,656 | 8,362 | $532K | |
| 87661 | Infectious agent detection by nucleic acid; Trichomonas vaginalis, amplified probe | 9.5% | 19,046 | 18,445 | $448K |
| 88175 | Cytopathology, cervical or vaginal, any reporting system; collected in preservative fluid, automated thin layer | 9.2% | 22,719 | 22,428 | $433K |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | 7.8% | 7,064 | 5,715 | $366K |
| 87624 | Infectious agent detection by nucleic acid; human papillomavirus (HPV), high-risk types | 7.0% | 13,151 | 12,964 | $326K |
| 87481 | 6.0% | 15,383 | 11,466 | $282K | |
| 87653 | 4.6% | 9,226 | 8,682 | $216K | |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | 2.6% | 1,834 | 1,693 | $123K |
| 88141 | 2.3% | 6,518 | 6,421 | $110K | |
| 88342 | 1.7% | 1,498 | 1,191 | $81K |
22 more codes
| 87511 | 1.1% | 3,211 | $53K | |
| 88142 | <1% | 2,839 | $41K | |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 | <1% | 1,543 | $34K |
| 88312 | <1% | 231 | $20K | |
| 87480 | <1% | 1,567 | $20K | |
| 88341 | <1% | 178 | $16K | |
| 88304 | <1% | 454 | $15K | |
| 87660 | <1% | 1,555 | $15K | |
| 87801 | Infectious agent detection by nucleic acid; amplified probe, multiple organisms | <1% | 266 | $15K |
| 87510 | <1% | 1,557 | $14K | |
| 87625 | <1% | 380 | $9K | |
| 88173 | <1% | 74 | $6K | |
| 87529 | <1% | 111 | $4K | |
| 87070 | <1% | 362 | $2K | |
| 88313 | <1% | 110 | $1K | |
| 87798 | Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism | <1% | 43 | $718.37 |
| 87186 | <1% | 53 | $187.87 | |
| 87075 | <1% | 42 | $183.19 | |
| 87205 | <1% | 77 | $182.12 | |
| 87077 | <1% | 14 | $30.75 | |
| G0476 | Infectious agent detection by nucleic acid (dna or rna); human papillomavirus (hpv), high-risk types (e.g., 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 68) for cervical cancer screening, must be performed in addition to pap test | 0% | 307 | $0.00 |
| G0145 | Screening cytopathology, cervical or vaginal (any reporting system), collected in preservative fluid, automated thin layer preparation, with screening by automated system and manual rescreening under physician supervision | 0% | 763 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialRUPNOW, SCOTT (CEO)
| Provider | Location | Paid |
|---|---|---|
| Pathology Associates of San Antonio, L.L.P. | San Antonio, TX | $969K |
| Foundations, INC. | San Antonio, TX | $37K |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.